```html

Fallopian Tube Infection (Salpingitis)

Overview

Salpingitis, also called fallopian tube infection, is inflammation and infection of one or both of the fallopian tubes—the structures that carry eggs from the ovaries to the uterus. It is most often a component of pelvic inflammatory disease (PID), a broader infection of the female reproductive organs.

• Who it affects: Women of reproductive age (15‑44 years) are at highest risk, but post‑menopausal women can develop salpingitis after procedures such as intrauterine device (IUD) insertion.
• Prevalence: In the United States, PID (which includes salpingitis) accounts for roughly 4.4 million visits to health‑care providers each year and is estimated to affect 1 % of women annually. Worldwide, > 5 % of women of child‑bearing age suffer at least one episode of PID during their lifetime.<sup>1</sup>
• Why it matters: Untreated infection can scar the tubes, leading to infertility, ectopic pregnancy, and chronic pelvic pain.

Symptoms

Symptoms can range from mild to severe and may appear suddenly or develop over several days. Not every woman experiences all of them.

• Pain in the lower abdomen or pelvis – Often described as a dull, constant ache that may worsen during intercourse or menstruation.
• Fever or chills – Body temperature ≥ 100.4 °F (38 °C) suggests a more serious infection.
• Abnormal vaginal discharge – Thick, purulent, or foul‑smelling discharge.
• Irregular menstrual bleeding – Spotting between periods or heavier bleeding.
• Painful urination or bowel movements – May mimic urinary tract infection.
• Nausea or vomiting – Especially if the infection has spread.
• Bleeding after intercourse (post‑coital spotting).
• General feeling of being unwell – Fatigue, malaise, or loss of appetite.

Causes and Risk Factors

Infectious agents

Most cases are bacterial, usually ascending from the lower genital tract.

• Sexually transmitted bacteria: Chlamydia trachomatis (most common) and Neisseria gonorrhoeae.
• Other bacteria: Mycoplasma genitalium, anaerobes (e.g., Bacteroides), and Gram‑negative rods such as E. coli.
• Post‑procedural infections: After IUD insertion, tubal ligation, endometrial biopsy, or laparoscopic surgery.

Risk factors

• Multiple or new sexual partners, especially without consistent condom use.
• Previous episode of PID or known chlamydia/gonorrhea infection.
• Intrauterine device (IUD) placement, particularly within the first 20 days.
• History of sexually transmitted infections (STIs).
• Pelvic surgery or procedures that breach the cervical barrier.
• Lower socioeconomic status and limited access to preventive health care.
• Smoking – impairs local immune defenses.

Diagnosis

Diagnosis combines a clinical evaluation with targeted tests.

Clinical assessment

• Detailed medical and sexual history.
• Physical exam focusing on abdominal tenderness, cervical motion tenderness, and adnexal (ovary/tube) pain.

Laboratory tests

• NAAT (Nucleic Acid Amplification Test): Most sensitive for C. trachomatis and N. gonorrhoeae from urine or cervical swab.
• Complete blood count (CBC) – May show elevated white blood cells.
• C‑reactive protein (CRP) or erythrocyte sedimentation rate (ESR) – Markers of inflammation.
• Pregnancy test – Essential before prescribing certain antibiotics.

Imaging

• Transvaginal ultrasound: Detects tubo‑ovarian abscess, fluid collections, or hydrosalpinx (fluid‑filled tube).
• Laparoscopy (diagnostic): Gold standard for severe or atypical cases; allows direct visualization and possible treatment.

Diagnostic criteria

The CDC’s clinical PID criteria require the presence of any two of the following:

1. Cervical motion tenderness
2. Adnexal tenderness
3. Uterine tenderness

When these are present with a compatible history, treatment is usually started before test results return.

Treatment Options

Antibiotic regimens (first‑line)

Guidelines from the CDC and WHO recommend combination therapy to cover both typical and resistant organisms.

Regimen	Duration	Comments
Cefoxitin 2 g IV every 6 h + Doxycycline 100 mg PO twice daily	14 days (IV 2–4 days, then oral)	Broad‑spectrum, covers anaerobes.
Cephalosporin (e.g., Ceftriaxone 250 mg IM) + Doxycycline 100 mg PO bid + Metronidazole 500 mg PO tid	14 days (all oral after single IM dose)	Preferred for outpatient care.

Alternative regimens

• Clindamycin 900 mg PO three times daily + Gentamicin 5 mg/kg IV daily.
• For penicillin‑allergic patients, replace β‑lactams with azithromycin (1 g PO single dose) plus metronidazole.

Hospitalization

Indicated when any of the following are present:

• Severe abdominal pain or high fever (> 101 °F/38.3 °C).
• Nausea/vomiting preventing oral intake.
• Pregnancy (risk of ectopic pregnancy).
• Tubo‑ovarian abscess > 9 cm or failure to improve after 48–72 h of antibiotics.

Surgical and procedural options

• Laparoscopic drainage of a tubo‑ovarian abscess.
• Salpingectomy (removal of the damaged tube) in cases of persistent infection, severe scarring, or recurrent PID.
• Fertility‑preserving procedures such as tube reconstructive surgery—considered only in select cases.

Lifestyle and supportive care

• Adequate hydration and rest.
• Pain control with acetaminophen or NSAIDs (if no contraindication).
• Avoid douching, scented products, and intra‑vaginal chemicals that disrupt normal flora.
• Partner notification and treatment to prevent reinfection.

Living with Fallopian Tube Infection (Salpingitis)

Even after successful treatment, many women need to manage ongoing symptoms or concerns.

Self‑care strategies

• Track symptoms: Keep a diary of pain, discharge, and menstrual changes to discuss with your provider.
• Heat therapy: A warm compress or heating pad can reduce pelvic cramping.
• Gentle exercise: Walking improves circulation without straining the pelvis.
• Nutrition: A balanced diet rich in vitamin C, zinc, and probiotics supports immune recovery.

Follow‑up care

Schedule a repeat pelvic exam 1–2 weeks after completing antibiotics and again at 3 months to ensure resolution. If you experience persistent pain or infertility concerns, ask for a referral to a reproductive endocrinologist.

Emotional well‑being

Experiencing a reproductive infection can be stressful. Consider counseling, support groups, or online communities (e.g., the CDC’s STI support resources) to address anxiety, especially around fertility worries.

Prevention

• Safe sex practices: Use latex condoms consistently; limit the number of sexual partners.
• Regular STI screening: At least annually for sexually active women under 25 years, and after any change in partners. Earlier if symptoms appear.
• Prompt treatment of chlamydia/gonorrhea: Even asymptomatic infections should be treated to prevent spread to the upper genital tract.
• Post‑procedure prophylaxis: Antibiotic prophylaxis is recommended after certain gynecologic surgeries; discuss with your surgeon.
• Vaccination: The HPV vaccine reduces risk of cervical abnormalities that can predispose to PID.
• Smoking cessation: Improves mucosal immunity and reduces infection risk.

Complications

If left untreated, salpingitis can lead to serious, sometimes irreversible outcomes.

• Infertility: Scarring (hydrosalpinx) blocks egg travel; up to 30 % of women with PID develop infertility.<sup>2</sup>
• Ectopic pregnancy: Damaged tubes increase the chance of implantation outside the uterus; risk rises 5‑fold after PID.
• Tubo‑ovarian abscess: A pus‑filled pocket that may require drainage or surgery.
• Chronic pelvic pain: Persistent discomfort lasting > 6 months, often requiring multidisciplinary pain management.
• Peritonitis: Rare but life‑threatening spread of infection into the abdominal cavity.
• Adhesions: Fibrous scar tissue that can cause bowel obstruction or affect other pelvic organs.

When to Seek Emergency Care

---

Sources: <sup>1</sup> Centers for Disease Control and Prevention. “Pelvic Inflammatory Disease (PID).” 2023. https://www.cdc.gov/std/pid/default.htm; <sup>2</sup> Mayo Clinic. “Pelvic inflammatory disease (PID): Causes, symptoms, and treatment.” 2022. https://www.mayoclinic.org/diseases-conditions/pid/symptoms-causes/syc-20376771; World Health Organization. “Sexually transmitted infections (STIs) fact sheet.” 2023; National Institutes of Health. “Chlamydia and fertility.” 2021.

```